BREVIBLOC

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Canada, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Japan, Malta, Romania, Spain, Turkey, UK.

Active ingredients

The drug BREVIBLOC contains one active pharmaceutical ingredient (API):

1	Esmolol UNII V05260LC8D - ESMOLOL HYDROCHLORIDE
	Esmolol is a beta-selective (cardioselective) receptor blocking agent. At therapeutic doses esmolol has no significant intrinsic sympathicomimetic activity (ISA) or membrane stabilising activity.
	Read more about Esmolol

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C07AB09	Esmolol	C Cardiovascular system → C07 Beta blocking agents → C07A Beta blocking agents → C07AB Beta blocking agents, selective
Discover more medicines within C07AB09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	506701601151414, 506701602156411, 506714120053803, 506717100073603, 506719010077703
CA	Health Products and Food Branch	02188880, 02309238
EE	Ravimiamet	1888252
ES	Centro de información online de medicamentos de la AEMPS	72349, 72608
FI	Lääkealan turvallisuus- ja kehittämiskeskus	097961, 097973
FR	Base de données publique des médicaments	61177887, 63922956
GB	Medicines & Healthcare Products Regulatory Agency	100725, 170340
HK	Department of Health Drug Office	57511, 57732
JP	医薬品医療機器総合機構	2123405A1023
MT	Medicines Authority	AA1277/02201, AA1277/02202
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68938001, W68956001
TR	İlaç ve Tıbbi Cihaz Kurumu	8681413880964, 8681413880971
US	FDA, National Drug Code	10019-055, 10019-075, 10019-115, 10019-666, 10019-668, 10019-670, 10019-672, 52584-115